Lower-Dose DMPA
Description: A single subcutaneous injection of medroxyprogesterone acetate injectable suspension, (dose between 45mg - 105mg), currently approved for intramusclar use, given every 3 months.
Product Details
Duration: 3 months plus at least 1 month grace period
Regimen:
Dose: TBD between 45mg -105mg
Active Pharmaceutical Ingredient (API):
Inactive material: polyethylene glycol 3350; polysorbate 80; sodium chloride; methylparaben; propylparaben; water for injection
Status Details
Began discovery in: 2013
Status Details: - Phase I study ongoing.
- Phase I study ongoing.
Additional Information
References: Shelton JD, Halpern V. (2014) Subcutaneous DMPA: a better lower dose approach. Contraception. 89(5):341-3.
Shelton JD, Halpern V. (2014) Subcutaneous DMPA: a better lower dose approach. Contraception. 89(5):341-3.